Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis. Ngwalero, P, Brust, J. C M, van Beek, S W, Wasserman, S., Maartens, G, Meintjes, G., Joubert, A, Norman, J, Castel, S, Gandhi, N R, Svensson, E M, & Wiesner, L. Antimicrobial Agents and Chemotherapy, 65(11):e02399–20, 2021. ![Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the intracellular concentrations of bedaquiline and its primary metabolite M2 in patients with RR-TB in South Africa. Twenty-one participants were enrolled and underwent sparse sampling of plasma and peripheral blood mononuclear cells (PBMCs) at months 1, 2, and 6 of treatment and at 3 and 6 months after bedaquiline treatment completion. Intensive sampling was performed at month 2. We used noncompartmental analysis to describe plasma and intracellular exposures and a population pharmacokinetic model to explore the relationship between plasma and intracellular pharmacokinetics and the effects of key covariates. Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 to 2,540 ng/ml in plasma and 16.2 to 5,478 ng/ml in PBMCs, and concentrations of M2 over the 6-month treatment period ranged from 34.3 to 496 ng/ml in plasma and 109.2 to 16,764 ng/ml in PBMCs. Plasma concentrations of bedaquiline were higher than those of M2, but intracellular concentrations of M2 were considerably higher than those of bedaquiline. In the pharmacokinetic modeling, we estimated a linear increase in the intracellular-plasma accumulation ratio for bedaquiline and M2, reaching maximum effect after 2 months of treatment. The typical intracellular-plasma ratios 1 and 2 months after start of treatment were 0.61 (95% confidence interval [CI]: 0.42 to 0.92) and 1.10 (95% CI: 0.74 to 1.63) for bedaquiline and 12.4 (95% CI: 8.8 to 17.8) and 22.2 (95% CI: 15.6 to 32.3) for M2. The intracellular-plasma ratios for both bedaquiline and M2 were decreased by 54% (95% CI: 24 to 72%) in HIV-positive patients compared to HIV-negative patients. Bedaquiline and M2 were detectable in PBMCs 6 months after treatment discontinuation. M2 accumulated at higher concentrations intracellularly than bedaquiline, supporting in vitro evidence that M2 is the main inducer of phospholipidosis.
@article{Ngwalero2021,
abstract = {Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the intracellular concentrations of bedaquiline and its primary metabolite M2 in patients with RR-TB in South Africa. Twenty-one participants were enrolled and underwent sparse sampling of plasma and peripheral blood mononuclear cells (PBMCs) at months 1, 2, and 6 of treatment and at 3 and 6 months after bedaquiline treatment completion. Intensive sampling was performed at month 2. We used noncompartmental analysis to describe plasma and intracellular exposures and a population pharmacokinetic model to explore the relationship between plasma and intracellular pharmacokinetics and the effects of key covariates. Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 to 2,540 ng/ml in plasma and 16.2 to 5,478 ng/ml in PBMCs, and concentrations of M2 over the 6-month treatment period ranged from 34.3 to 496 ng/ml in plasma and 109.2 to 16,764 ng/ml in PBMCs. Plasma concentrations of bedaquiline were higher than those of M2, but intracellular concentrations of M2 were considerably higher than those of bedaquiline. In the pharmacokinetic modeling, we estimated a linear increase in the intracellular-plasma accumulation ratio for bedaquiline and M2, reaching maximum effect after 2 months of treatment. The typical intracellular-plasma ratios 1 and 2 months after start of treatment were 0.61 (95{\%} confidence interval [CI]: 0.42 to 0.92) and 1.10 (95{\%} CI: 0.74 to 1.63) for bedaquiline and 12.4 (95{\%} CI: 8.8 to 17.8) and 22.2 (95{\%} CI: 15.6 to 32.3) for M2. The intracellular-plasma ratios for both bedaquiline and M2 were decreased by 54{\%} (95{\%} CI: 24 to 72{\%}) in HIV-positive patients compared to HIV-negative patients. Bedaquiline and M2 were detectable in PBMCs 6 months after treatment discontinuation. M2 accumulated at higher concentrations intracellularly than bedaquiline, supporting in vitro evidence that M2 is the main inducer of phospholipidosis.},
author = {Ngwalero, P and Brust, James C M and van Beek, S W and Wasserman, Sean and Maartens, G and Meintjes, Graeme and Joubert, A and Norman, J and Castel, S and Gandhi, N R and Svensson, E M and Wiesner, Lubbe},
doi = {10.1128/AAC.02399-20},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Ngwalero et al. - 2021 - Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South Afri.pdf:pdf},
journal = {Antimicrobial Agents and Chemotherapy},
keywords = {OA,fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,original},
number = {11},
pages = {e02399--20},
pmid = {34370588},
title = {{Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis}},
url = {https://journals.asm.org/doi/10.1128/AAC.02399-20},
volume = {65},
year = {2021}
}
Downloads: 0
{"_id":"Ar5awLNiBNRKYQLcG","bibbaseid":"ngwalero-brust-vanbeek-wasserman-maartens-meintjes-joubert-norman-etal-relationshipbetweenplasmaandintracellularconcentrationsofbedaquilineanditsm2metaboliteinsouthafricanpatientswithrifampinresistanttuberculosis-2021","author_short":["Ngwalero, P","Brust, J. C M","van Beek, S W","Wasserman, S.","Maartens, G","Meintjes, G.","Joubert, A","Norman, J","Castel, S","Gandhi, N R","Svensson, E M","Wiesner, L."],"bibdata":{"bibtype":"article","type":"article","abstract":"Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the intracellular concentrations of bedaquiline and its primary metabolite M2 in patients with RR-TB in South Africa. Twenty-one participants were enrolled and underwent sparse sampling of plasma and peripheral blood mononuclear cells (PBMCs) at months 1, 2, and 6 of treatment and at 3 and 6 months after bedaquiline treatment completion. Intensive sampling was performed at month 2. We used noncompartmental analysis to describe plasma and intracellular exposures and a population pharmacokinetic model to explore the relationship between plasma and intracellular pharmacokinetics and the effects of key covariates. Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 to 2,540 ng/ml in plasma and 16.2 to 5,478 ng/ml in PBMCs, and concentrations of M2 over the 6-month treatment period ranged from 34.3 to 496 ng/ml in plasma and 109.2 to 16,764 ng/ml in PBMCs. Plasma concentrations of bedaquiline were higher than those of M2, but intracellular concentrations of M2 were considerably higher than those of bedaquiline. In the pharmacokinetic modeling, we estimated a linear increase in the intracellular-plasma accumulation ratio for bedaquiline and M2, reaching maximum effect after 2 months of treatment. The typical intracellular-plasma ratios 1 and 2 months after start of treatment were 0.61 (95% confidence interval [CI]: 0.42 to 0.92) and 1.10 (95% CI: 0.74 to 1.63) for bedaquiline and 12.4 (95% CI: 8.8 to 17.8) and 22.2 (95% CI: 15.6 to 32.3) for M2. The intracellular-plasma ratios for both bedaquiline and M2 were decreased by 54% (95% CI: 24 to 72%) in HIV-positive patients compared to HIV-negative patients. Bedaquiline and M2 were detectable in PBMCs 6 months after treatment discontinuation. M2 accumulated at higher concentrations intracellularly than bedaquiline, supporting in vitro evidence that M2 is the main inducer of phospholipidosis.","author":[{"propositions":[],"lastnames":["Ngwalero"],"firstnames":["P"],"suffixes":[]},{"propositions":[],"lastnames":["Brust"],"firstnames":["James","C","M"],"suffixes":[]},{"propositions":["van"],"lastnames":["Beek"],"firstnames":["S","W"],"suffixes":[]},{"propositions":[],"lastnames":["Wasserman"],"firstnames":["Sean"],"suffixes":[]},{"propositions":[],"lastnames":["Maartens"],"firstnames":["G"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme"],"suffixes":[]},{"propositions":[],"lastnames":["Joubert"],"firstnames":["A"],"suffixes":[]},{"propositions":[],"lastnames":["Norman"],"firstnames":["J"],"suffixes":[]},{"propositions":[],"lastnames":["Castel"],"firstnames":["S"],"suffixes":[]},{"propositions":[],"lastnames":["Gandhi"],"firstnames":["N","R"],"suffixes":[]},{"propositions":[],"lastnames":["Svensson"],"firstnames":["E","M"],"suffixes":[]},{"propositions":[],"lastnames":["Wiesner"],"firstnames":["Lubbe"],"suffixes":[]}],"doi":"10.1128/AAC.02399-20","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Ngwalero et al. - 2021 - Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South Afri.pdf:pdf","journal":"Antimicrobial Agents and Chemotherapy","keywords":"OA,fund_ack,original","mendeley-tags":"OA,fund_ack,original","number":"11","pages":"e02399–20","pmid":"34370588","title":"Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis","url":"https://journals.asm.org/doi/10.1128/AAC.02399-20","volume":"65","year":"2021","bibtex":"@article{Ngwalero2021,\r\nabstract = {Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the intracellular concentrations of bedaquiline and its primary metabolite M2 in patients with RR-TB in South Africa. Twenty-one participants were enrolled and underwent sparse sampling of plasma and peripheral blood mononuclear cells (PBMCs) at months 1, 2, and 6 of treatment and at 3 and 6 months after bedaquiline treatment completion. Intensive sampling was performed at month 2. We used noncompartmental analysis to describe plasma and intracellular exposures and a population pharmacokinetic model to explore the relationship between plasma and intracellular pharmacokinetics and the effects of key covariates. Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 to 2,540 ng/ml in plasma and 16.2 to 5,478 ng/ml in PBMCs, and concentrations of M2 over the 6-month treatment period ranged from 34.3 to 496 ng/ml in plasma and 109.2 to 16,764 ng/ml in PBMCs. Plasma concentrations of bedaquiline were higher than those of M2, but intracellular concentrations of M2 were considerably higher than those of bedaquiline. In the pharmacokinetic modeling, we estimated a linear increase in the intracellular-plasma accumulation ratio for bedaquiline and M2, reaching maximum effect after 2 months of treatment. The typical intracellular-plasma ratios 1 and 2 months after start of treatment were 0.61 (95{\\%} confidence interval [CI]: 0.42 to 0.92) and 1.10 (95{\\%} CI: 0.74 to 1.63) for bedaquiline and 12.4 (95{\\%} CI: 8.8 to 17.8) and 22.2 (95{\\%} CI: 15.6 to 32.3) for M2. The intracellular-plasma ratios for both bedaquiline and M2 were decreased by 54{\\%} (95{\\%} CI: 24 to 72{\\%}) in HIV-positive patients compared to HIV-negative patients. Bedaquiline and M2 were detectable in PBMCs 6 months after treatment discontinuation. M2 accumulated at higher concentrations intracellularly than bedaquiline, supporting in vitro evidence that M2 is the main inducer of phospholipidosis.},\r\nauthor = {Ngwalero, P and Brust, James C M and van Beek, S W and Wasserman, Sean and Maartens, G and Meintjes, Graeme and Joubert, A and Norman, J and Castel, S and Gandhi, N R and Svensson, E M and Wiesner, Lubbe},\r\ndoi = {10.1128/AAC.02399-20},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Ngwalero et al. - 2021 - Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South Afri.pdf:pdf},\r\njournal = {Antimicrobial Agents and Chemotherapy},\r\nkeywords = {OA,fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nnumber = {11},\r\npages = {e02399--20},\r\npmid = {34370588},\r\ntitle = {{Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis}},\r\nurl = {https://journals.asm.org/doi/10.1128/AAC.02399-20},\r\nvolume = {65},\r\nyear = {2021}\r\n}\r\n","author_short":["Ngwalero, P","Brust, J. C M","van Beek, S W","Wasserman, S.","Maartens, G","Meintjes, G.","Joubert, A","Norman, J","Castel, S","Gandhi, N R","Svensson, E M","Wiesner, L."],"key":"Ngwalero2021","id":"Ngwalero2021","bibbaseid":"ngwalero-brust-vanbeek-wasserman-maartens-meintjes-joubert-norman-etal-relationshipbetweenplasmaandintracellularconcentrationsofbedaquilineanditsm2metaboliteinsouthafricanpatientswithrifampinresistanttuberculosis-2021","role":"author","urls":{"Paper":"https://journals.asm.org/doi/10.1128/AAC.02399-20"},"keyword":["OA","fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","wrEvssexmuYudwQw9","9bX4N36CTXtCXNFMd","6GMFi5DCojy3jHY44"],"keywords":["oa","fund_ack","original"],"search_terms":["relationship","between","plasma","intracellular","concentrations","bedaquiline","metabolite","south","african","patients","rifampin","resistant","tuberculosis","ngwalero","brust","van beek","wasserman","maartens","meintjes","joubert","norman","castel","gandhi","svensson","wiesner"],"title":"Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis","year":2021}